# An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT02305563** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 70 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** BMS-936564
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02305563
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-27
- **Primary completion:** 2019-06-04
- **Final completion:** 2019-06-04
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Business objectives have changed, slow accrual, the standard of care for the patient population changed and we were unable to accrue any longer.
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02305563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02305563, "An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02305563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*